Lactate Dehydrogenase-to-Albumin Ratio Predicts 30-Day and 90-Day Mortality in Glucocorticoid-Treated ICU Patients With Pneumonia: A Secondary Analysis of a Multicenter Cohort - Scorecard - MDSpire

Lactate Dehydrogenase-to-Albumin Ratio Predicts 30-Day and 90-Day Mortality in Glucocorticoid-Treated ICU Patients With Pneumonia: A Secondary Analysis of a Multicenter Cohort

  • By

  • Han, Dan dan

  • Sun, fa Sheng

  • Liu, Ai

  • Hao, Cuiping

  • Sun, ping Jian

  • April 16, 2026

  • 0 min

Share

Clinical Scorecard: Lactate Dehydrogenase to Albumin Ratio as a Predictor of 30-Day and 90-Day Mortality in ICU Patients with Pneumonia Undergoing Glucocorticoid Treatment: Insights from a Secondary Analysis of a Multicenter Study

At a Glance

CategoryDetail
ConditionPneumonia in ICU patients receiving glucocorticoids
Key MechanismsLactate dehydrogenase-to-albumin ratio (LAR) reflects cellular injury and nutritional reserve
Target PopulationICU patients with pneumonia undergoing glucocorticoid treatment
Care SettingIntensive Care Unit (ICU)

Key Highlights

  • Optimal LAR cutoff for 30-day mortality is 13.39.
  • High LAR (≥13.39) correlates with increased 30-day (45.8%) and 90-day (51.4%) mortality.
  • High LAR remains an independent predictor of mortality after multivariable adjustment.
  • LAR provides significant incremental prognostic value when added to the PSI score.
  • LAR demonstrates good discrimination with an AUC of approximately 0.74.

Guideline-Based Recommendations

Diagnosis

  • Utilize LAR as a prognostic tool in pneumonia patients receiving glucocorticoids.

Management

  • Incorporate LAR into clinical assessments for early risk stratification.

Monitoring & Follow-up

  • Monitor LAR levels to guide individualized management strategies.

Risks

  • High LAR is associated with significantly higher mortality rates at 30 and 90 days.

Patient & Prescribing Data

ICU patients with pneumonia on glucocorticoids

LAR is a steroid-resilient biomarker that aids in risk stratification.

Clinical Best Practices

  • Consider LAR in conjunction with other clinical scores for comprehensive assessment.
  • Regularly assess LAR to adjust treatment plans based on mortality risk.

References

    Original Source(s)

    Related Content